Skip to main content

Pediatrics

Pediatrics Research

Overview

Our goal at the Center for Pediatric Research is to create the future of pediatric health care through research and data analysis to improve clinical performance and quality of care. We seek to increase the ability of AdventHealth for Children to become a leading children’s network and to extend the healing ministry of Christ.

AdventHealth for Children has over 135 highly skilled pediatric specialists covering more than 35 pediatric sub-specialties currently providing consultation services to the unit. Comprehensive sub-specialty care includes the Johns Hopkins Children’s Heart Surgery program, a Level IV Comprehensive Pediatric Epilepsy Center, Level III Neonatal Intensive Care Unit (NICU), Cancer and Blood Disorder specialty with a pediatric bone marrow transplant program, a Pediatric Liver Transplant program, and a Complex Care Clinic for patients with complex diagnoses. Interdisciplinary rounds occur every day on each patient. 

AdventHealth for Children has been recognized for excellence in nursing by being awarded Magnet status in 2012 and re-designation in 2016. AdventHealth for Children has been recognized by U.S. News & World Report as the Best Children’s Hospital for newborn care in Florida for the second year in a row.

Contact Information

Center for Pediatric Research

Areas of Focus

  • Asthma
  • Autism
  • Cardiology
  • Dermatology
  • Hematology
  • Hepatology
  • Neonatology 
  • Orthopedics
  • Rheumatology and Immunology
  • Sepsis (infections)
  • Pediatric obesity
  • Urology
  • Vaccines

Featured Clinical Trials

NCT04974528

INHALE-1: A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus

Icon for trial | MKC-TI-155 Part 2 INHALE-1: A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insu

This study is currently enrolling.

You are being asked to take part in this research study because you have type 1 or type 2 diabetes. Diabetes is a condition in which your body has trouble controlling your blood glucose (sugar) levels on its own. The goal of th ...

NCT05778188

A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns with Moderate or Severe Hypoxic Ischemic Encephalopathy Undergoing Therapeutic Hypothermia with Long-Term Follow-Up (STAR)

Icon for trial | RLS-0071-202 A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns with Moderate or Severe Hypoxic Ischemi

This study is currently enrolling.

This study is being conducted to learn whether the investigational medication, called RLS-0071, may help babies, such as your own, who are affected by hypoxic-ischemic encephalopathy (HIE). HIE is a disease process where the ba ...

Meet the Team

Our Capabilities

  • 82 licensed beds in Women’s Hospital
  • 20 beds in Children’s Hospital
  • 2 neonatal transport teams 
  • 12 neonatologists and a dedicated interdisciplinary team (pharmacists, nutritionists, clinical social workers, nurse discharge coordinators, speech therapists, occupational/physical therapists, lactation consultants, and child life specialists)